Loading organizations...
Loading organizations...
Key people at Med-Fine Capital.
Key people at Med-Fine Capital.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 25, 2025 | Phrontline Biopharma | $60.0M Pre-Series A | 王及 | Decheng Capital, Samsung, Sino Biopharmaceutical |
| Nov 28, 2024 | Allink Biotherapeutics | $42.0M Series A | — | Jiangtao Yu, Legend Capital, Vince Deng |
| Feb 1, 2024 | Rebbeca Med | $9.1M Series A | 周玉建 | — |
| Jun 10, 2022 | Degron Therapeutics | $22.0M Series A | jing yu | Baidu Ventures, Co-win Ventures, Dyee Capital, NeuX Capital |
| Nov 24, 2021 | Allorion Therapeutics | $40.0M Series A | Qiming Venture Partners | IDG Capital, Octagon Capital, TF Capital |
| Aug 29, 2021 | LYNK Pharmaceuticals | $50.0M Series B | Lilly Asia Ventures | HEDA Ventures, Legend Capital, New Alliance Capital |
| May 10, 2021 | Alebund Pharmaceuticals | $60.0M Series B | Quan Capital | 3E Bioventures Capital, Lilly Asia Ventures, Sherpa Healthcare Partners |
| Excalipoint Therapeutics | $28.0M Excalipoint Therapeutics Seed Extension | Centurium Capital, Matrix Partners China, Vicky Li, David Su | 5Y Capital, Apricot Capital, Co-win Ventures, Eisai Innovation, Hony Capital, Lilly Asia Ventures, Sequoia Capital |